Dermatology

Genetic analysis shows higher BMI increases hidradenitis suppurativa risk, while smoking evidence is inconclusive. The study also supports a causal link with IBD.

Vixarelimab significantly reduced itch severity and improved skin clearance in patients with prurigo nodularis in a phase 2b randomized clinical trial.

New epidemiological data reveal long serial intervals and sustained scabies transmission in Europe, highlighting how modest prevention could curb epidemic growth.

High-throughput proteomics identifies inflammatory clusters and biomarkers associated with disease severity and treatment response in bullous pemphigoid.

A Pan-European study reports high rates of addictive behaviours among patients with chronic skin diseases, linked to poorer quality of life and key demographic factors.

Most systemic therapy-naïve patients with moderate-to-severe atopic dermatitis or psoriasis in Germany wish to escalate treatment, with clear preferences for administration route.

A large, multiethnic study reveals distinct facial microbiota patterns in adolescents with acne, identifying key bacterial species linked to acne pathology.

A new Nordic study reports no clear increase in major congenital malformations among infants exposed to topical retinoids in early pregnancy.

New research shows metabolic liver disease is linked to increased androgenetic alopecia risk, with stronger effects in women and those with unhealthy lifestyle patterns.

Fibroblasts fuel skin and systemic inflammation via a CXCL10–glycolysis axis in dermatomyositis, offering new metabolic treatment opportunities.

A phase 3 trial shows dupilumab significantly improves quality of life in omalizumab-naïve patients with chronic spontaneous urticaria.

IMCAS World Congress 2026 unites global dermatology experts to explore advances in science, aesthetics, and complication management across lasers, dermatology, and injectables.

New phase 3 trial finds ivarmacitinib ointment provides rapid, lasting relief from mild-to-moderate eczema with a favourable safety profile.

A large retrospective study shows JAK2 gene fusion occurs in both aggressive and indolent cutaneous T-cell lymphomas, offering new insight into diagnosis and targeted treatment.

Swedish study shows patients with stage IIC melanoma have poorer survival than stage IIIA, highlighting need for closer follow-up and treatment.

A phase 1b/2a trial reports that stapokibart is well tolerated and improves symptoms in children aged 6–11 years with moderate-to-severe atopic dermatitis.

A new trial finds maternal prebiotic supplementation during pregnancy does not prevent atopic dermatitis in high-risk infants at one year of age.

Lupus-like disease linked to MDS/CMML shows distinct features and poor response to standard treatment, improving with clone-directed therapy.

GLP-1 agonists are more often prescribed for hidradenitis suppurativa patients with obesity, diabetes, and other metabolic conditions.

A study shows adding oral ivermectin to permethrin improves cure rates and speeds symptom relief in children with persistent scabies, with regular follow-up over several months.

Survivors of SJS/TEN report lasting physical, psychological, and social effects, with major gaps in post-discharge care and support highlighted in a new qualitative study.

Researchers demonstrate how cross-modal imaging can noninvasively identify histologic features of skin, advancing precision in dermatologic diagnosis.

A major cohort study involving over 20 million patients found that seborrheic dermatitis was significantly associated with several epithelial barrier diseases.

A UK online trial found that daily and weekly bathing make no difference to eczema symptoms.

Recent research has demonstrated that copy-number variants play a central role in acquired ICI resistance.

Recent research has highlighted the potential of barzolvolimab, a first-in-class monoclonal antibody developed to inhibit the KIT receptor.

The relationship between physical activity and psychological wellbeing in vitiligo has gained attention in recent years.

A new study identifies active rash, interstitial lung disease, and elevated neutrophil-to-lymphocyte ratio as key predictors of in-hospital death among patients with dermatomyositis.

Recent research highlights programmed cell death mechanisms, apoptosis and necroptosis, as central to Stevens-Johnson syndrome and toxic epidermal necrolysis pathology.

Overall, the research suggests that incorporating T-cell receptor clonotype biomarkers into routine clinical assessment could significantly enhance risk stratification.

Diabetes and psoriasis together increase risk of all-cause and cancer mortality, according to a U.S. population study.

Social appearance anxiety was strongly linked to higher general anxiety, depressive symptoms, and reduced quality of life.

Discover a study showing how hydrocolloid dressing provides scar appearance comparable to daily petroleum ointment, with improved comfort and convenience for patients.

This new study examined whether stressful life factors in early childhood increase the likelihood of developing psoriasis later in life.

Crucially, most of the TFS period with the combination therapy was spent without severe toxicity, reflecting an improved quality of life.

This finding highlights that even small differences may have meaningful public health implications, given the high global prevalence of AD.

The results demonstrated a measurable improvement in acne lesion counts and significant shifts in the skin microbiota.

Many participants reported that a lack of understanding about skin cancer symptoms led to delays in seeking medical help.

A risk-stratified approach significantly enhanced skin cancer detection after organ transplantation without increasing health care burden.

In a single-centre, randomised, double-blind, sham-controlled clinical trial, 72 patients with ETR were enrolled to assess the efficacy of taVNS compared with sham stimulation.

AI tools achieve high accuracy diagnosing both STIs and anogenital dermatoses from clinical images, but more validation is needed.

Discover a study revealing how the seboselective 1726-nm laser delivers safe, long-lasting acne treatment results with improved skin clarity and confidence.

Discover a study on oral povorcitinib for vitiligo, showing significant repigmentation and safety in patients with extensive nonsegmental vitiligo.

A recent post hoc analysis used data from a Phase III trial of the new interleukin (IL)-17A inhibitor, vunakizumab, to explore predictors of early response.

Skin-to-skin contact in hospital helps very preterm infants develop stronger brain pathways for stress and emotions.

The International Psoriasis Council (IPC) has outlined clear criteria to help clinicians determine when systemic therapy should be prioritised.

Discover a study showing how neoadjuvant immunotherapy with tiragolumab and atezolizumab improves response rates and safety in high-risk Stage III melanoma.

In a randomised, placebo-controlled trial, researchers evaluated VC-H1, a hibiscus enzyme extract, as an oral plant-based collagen alternative for photoaged skin.

The study demonstrated that [99mTc]Tc-Tilmanocept could detect secondary lesions in patients with melanoma undergoing ICI treatment.

Discover a study exploring how hyaluronic acid and amino acids work together to accelerate healing in hard-to-heal wounds.

Oral isotretinoin remains the most effective therapy, although its precise mechanism is not fully understood.

Patients receiving once-daily upadacitinib 30 mg achieved significantly greater reductions in abscesses and inflammatory nodules compared with historical placebo rates.

The results revealed that patients with AD displayed a less favourable cardiovascular risk profile.

Beyond disease associations, CPAP mask-related skin complications such as dermatitis may arise due to friction, pressure, moisture, or sensitivity to mask materials.

A key finding was that patients treated at specialist centres experienced a significantly shorter delay in switching from immunosuppressants to advanced systemic therapies.

In Cohort 1, data from 787 participants revealed that current smokers, who comprised 53.9% of the group, were more likely to present with severe disease.